Efeito nefroprotetor do panax notoginseng
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2024.208095Palavras-chave:
Lesão renal aguda, Insuficiência renal crônica, Nefropatias diabéticas, Panax notoginsengResumo
Objetivo: Esta revisão sistemática teve como objetivo avaliar o efeito nefroprotetor do Panax notoginseng. Métodos: A busca por artigos científicos na literatura foi realizada nas bases de dados Medline (PubMed), Web of Science, Embase e Biblioteca Virtual em Saúde (BVS). Os critérios de elegibilidade incluíram estudos pré-clínicos in vivo ou clínicos que demonstraram o efeito nefroprotetor do Panax notoginseng, avaliado por meio de um ou mais dos seguintes exames laboratoriais: creatinina sérica, ureia sérica, taxa de filtração glomerular, clearance de creatinina, proteinúria e albuminúria. Resultados: Foram incluídos 14 artigos, todos consistindo em ensaios pré-clínicos. Os modelos de nefropatia utilizados pelos estudos foram a doença renal diabética (n=8), lesão renal induzida por substâncias nefrotóxicas (n=5) e lesão renal por isquemia (n=1). Todos os estudos demonstraram que o Panax notoginseng possui efeito nefroprotetor no tratamento das nefropatias. Apesar de três estudos não terem observado redução nos níveis séricos de creatinina e/ou ureia, verificou-se que a albuminúria diminuiu significativamente. Conclusão: O Panax notoginseng apresenta efeito nefroprotetor em diferentes modelos animais de nefropatia. O uso clínico do Panax notoginseng é promissor como adjuvante na farmacoterapia de disfunções renais e na prevenção da nefrotoxicidade induzida por medicamentos.
Downloads
Referências
Tang X, Huang M, Jiang J, Liang X, Li X, Meng R, et al. Panax notoginseng preparations as adjuvant therapy for diabetic kidney disease: a systematic review and meta-analysis. Pharm Biol. 2020; 58:138–45.
Zhang X, Zhou C, Miao L, et al. Panax Notoginseng Protects against Diabetes-Associated Endothelial Dysfunction: Comparison between Ethanolic Extract and Total Saponin. Oxid Med Cell Longev 2021; 2021:4722797. 10.1155/2021/4722797
Liu HB, Lu XY, Hu Y, Fan XH. Chemical constituents of Panax ginseng and Panax notoginseng explain why they differ in therapeutic efficacy. Pharmacol Res. 2020; 161:105263.
Chen Z, Li J, Liu J, Zhao Y, Zhang P, Zhang M, Zhang L. Saponins isolated from the root of Panax notoginseng showed significant anti-diabetic effects in KK-Ay mice. Am. J. Chin. Med. 2008; 36: 939-951.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S): S1–S127.
Sá J, Canani L, Rangel E, Bauer A, Escott G, Zelmanovitz T, Silveiro S, Bertoluci M. Doença renal do diabetes. Diretriz Oficial da Sociedade Brasileira de Diabetes (2022). DOI: 10.29327/557753.2022-18, ISBN: 978-65-5941-622-6.
Li J, Qiu P, Wang S, Wu J, He Q, Li K, et al. β-N-Oxalyl-L-α,β-diaminopropionic acid from Panax notoginseng plays a major role in the treatment of type 2 diabetic nephropathy. Biomed. Pharmacother. 2019; 114:108801. doi: 10.1016/j.biopha.2019.108801
Perazella MA. Pharmacology behind common drug nephrotoxicities. Clin J Am Soc Nephrol 2018; 13: 1897–1908
Zhang Y, Chi X, Wang Z, et al. Protective effects of Panax notoginseng saponins on PME-Induced nephrotoxicity in mice. Biomed Pharmacother. 2019; 116:108970.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71
Hooijmans C, Rovers M, De Vries R, Leenaars M, Ritskes-Hoitinga M, Langendam M. SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol. 2014; 14:1-9.
Liang X, Yang Y, Huang Z, Zhou J, Li Y, Zhong X. Panax notoginseng saponins mitigate cisplatin induced nephrotoxicity by inducing mitophagy via HIF-1alpha. Oncotarget. 2017;8:102989–3003.
Liu X, Huang Z, Zou X, Yang Y, Qiu Y, Wen Y. Panax notoginseng saponins attenuates cisplatin-induced nephrotoxicity via inhibiting the mitochondrial pathway of apoptosis. Int. J. Clin. Exp. Pathol. 2017; 7(12): 8391-8400.
Liu WJ, Tang HT, Jia YT, Ma B, Fu JF, Wang Y, Lv KY and Xia ZF: Notoginsenoside R1 attenuates renal ischemia-reperfusion injury in rats. Shock. 2010; 34:314–320.
Liu SJ, Zhou SW. Panax notoginseng saponins attenuated cisplatin-induced nephrotoxicity. Acta Pharmacol. 2000; 21(3): 257-260
Du YG, Wang LP, Qian JW, Zhang KN, Chai KF. Panax notoginseng saponins protect kidney from diabetes by up-regulating silent information regulator 1 and activating antioxidant proteins in rats. Chin. J. Integr. Med. 2016; 22: 910–917
Xue R, Zhai R, Xie L, Zheng Z, Jian G, Chen T, Su J, Gao C, Wang N, Yang X, Xu Y, Gui D. Xuesaitong protects podocytes from apoptosis in diabetic rats through modulating PTEN-PDK1-Akt-mTOR Pathway. J Diabetes Res. 2020;12.
Tu Q, Qin J, Dong H, Lu F, Guan W. Effects of Panax notoginoside on the expression of TGF-β1 and Smad-7 in renal tissues of diabetic rats. J Huazhong Univ Sci Technolog Med Sci. 2011; 31:190–193. doi: 10.1007/s11596-011-0250-5.
Zhang B, Zhang X, Zhang C, Shen Q, Sun G, Sun X. Notoginsenoside R1 Protects db/db Mice against Diabetic Nephropathy via Upregulation of Nrf2-Mediated HO-1 Expression. Molecules. 2019; 24(247).
Tu QN, Dong H, Lu FE. Effects of panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus. Chin J Integr Med. 2011;17:612–615.
Xie L, Zhai R, Chen T, Gao C, Xue R, Wang N, et al. Panax Notoginseng Ameliorates Podocyte EMT by Targeting the Wnt/β-Catenin Signaling Pathway in STZ-Induced Diabetic Rats. Drug Design Dev Ther. 2020;14:527–538.
Guo Y, Hu M, Ma J, Chinnathambi A, Alharbi SA, Shair OHM, et al. Protective effect of panaxydol against repeated administration of aristolochic acid on renal function and lipid peroxidation products via activating Keap1-Nrf2/ARE pathway in rat kidney. J Biochem Mol Toxicol. 2020;35:e22619.
Zhai R, Jian G, Chen T, Xie L, Xue R, Gao C, Wang N, Xu Y, Gui D (2019) Astragalus membranaceus and Panax notoginseng, the novel renoprotective compound, synergistically protect against podocyte injury in streptozotocin-induced diabetic rats. J Diabetes Res. 2019; 1:1–14.
American Diabetes Association. Standards of medical care in diabetes—2021. Diabetes Care. 2021;45.
Burtis C, Ashwood E, Bruns D. Tietz Fundamentos de Química Clínica. 6. ed. Rio de Janeiro: Elsevier, 2008.
Sociedade Brasileira De Diabetes (BR); Sociedade Brasileira De Endocrinologia E Metabologia (BR); Sociedade Brasileira De Nefrologia (BR). Posicionamento Oficial Tripartite nº 01/2016 SBD / SBEM / SBN: PREVENÇÃO, DIAGNÓSTICO E CONDUTA TERAPÊUTICA NA DOENÇA RENAL DO DIABETES. 2016; 01/2016:100.
Hayden M, Ghosh S. Regulation of NF-κB by TNF family cytokines. Semin. Immunol. 2014; 26(3): 253–266.
Li Q, Liang X, Yang Y, Zeng X, Zhong X, Huang C. Panax notoginseng saponins ameliorate cisplatin-induced mitochondrial injury via the HIF-1alpha/mitochondria/ROS pathway. FEBS Open Bio. 2020; 10: 118–126.
Nomura M, Iwasaki H, Suzuki N, Murata A, Iwamoto T, Kitamura K, Takamura Y, Koide M, Murakoshi M, Nishino H. Potent Anti-Hyperglycemic Effects of Panax Notoginseng Extract Containing Dammarane-Type Triterpenes in Human Subjects. CLINICAL THERAPEUTICS/NEW TECHNOLOGY—GLUCOSE MONITORING AND SENSING: ADA-Funded Research, Diabetes Journal. 2013; 62: A296-A297.
Wang T, Guo R, Zhou G, Zhou X, Kou Z, Sui F, et al. Traditional uses, botany, phytochemistry, pharmacology and toxicology of Panax notoginseng (Burk.) FH Chen: a review. J Ethnopharmacol. 2016;188:234–58.
AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA (BR). Guia para a condução de estudos não clínicos de toxicologia e segurança farmacológica necessários ao desenvolvimento de medicamentos. GESEF. 2nd ed. Brasília; 2013. 48 p.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2024 Gabriela Ayumi Miyata, Caroline Pereira Domingueti
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
